Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Hydreight Technologies Inc ( (TSE:NURS) ) is now available.
Hydreight Technologies Inc. has made a strategic $300,000 equity investment in Insu Therapeutics Inc., a biopharmaceutical firm developing a patent-pending buccal drug-delivery platform that aims to administer complex peptide therapeutics such as insulin and GLP-1 agonists without needles. The deal, structured as units of Insu shares and warrants paid half in cash and half in Hydreight shares and pending TSX Venture Exchange approval, aligns Hydreight with emerging needle-free delivery technology in a rapidly growing peptide therapeutics market exceeding US$40 billion, potentially enhancing patient adherence and positioning the company to benefit from innovations in GLP-1 and metabolic health treatments.
The most recent analyst rating on (TSE:NURS) stock is a Buy with a C$9.50 price target. To see the full list of analyst forecasts on Hydreight Technologies Inc stock, see the TSE:NURS Stock Forecast page.
More about Hydreight Technologies Inc
Hydreight Technologies Inc. is a Vancouver-based provider of digital healthcare infrastructure and mobile clinical services operating across the U.S. market. The company focuses on technology-enabled delivery of healthcare, positioning itself at the intersection of telehealth, mobile medicine, and wellness services, with an emphasis on scalable, patient-centric care solutions.
Average Trading Volume: 135,145
Technical Sentiment Signal: Hold
Current Market Cap: C$147.9M
For an in-depth examination of NURS stock, go to TipRanks’ Overview page.